Skip to content

Enasidenib mesylate

Idhifa (enasidenib mesylate) is a small molecule pharmaceutical. Enasidenib mesylate was first approved as Idhifa on 2017-08-01. It is used to treat myeloid leukemia acute in the USA. Idhifa's patents are valid until 2034-09-16 (FDA).
Trade Name Idhifa
Common Name Enasidenib mesylate
Indication myeloid leukemia acute
Drug Class Mutated isocitrate dehydrogenase (IDH) inhibitors
Enasidenib mesylate
Get full access now